Acute myeloid leukemia in children: Current status and future directions
- 10 February 2016
- journal article
- review article
- Published by Wiley in Pediatrics International
- Vol. 58 (2), 71-80
- https://doi.org/10.1111/ped.12865
Abstract
Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia and affects approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has improved through advances in chemotherapy, hematopoietic stem cell transplantation (HSCT), supportive care, and optimal risk stratification. Currently, clinical pediatric AML studies are conducted separately according to the AML subtypes: de novo AML, acute promyelocytic leukemia (APL), and myeloid leukemia with Down syndrome (ML-DS). Children with de novo AML are treated mainly with anthracyclines and cytarabine, in some cases with HSCT, and the overall survival (OS) rate now approaches 70%. Children with APL are treated with an all-trans retinoic acid (ATRA)-combined regimen with an 80-90% OS. Children with ML-DS are treated with a less intensive regimen compared with non-DS patients, and the OS is approximately 80%. HSCT in first remission is restricted to children with high-risk de novo AML only. To further improve outcomes, it will be necessary to combine more accurate risk stratification strategies using molecular genetic analysis with assessment of minimum residual disease, and the introduction of new drugs in international collaborative clinical trials.Keywords
This publication has 82 references indexed in Scilit:
- Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study GroupJournal of Clinical Oncology, 2013
- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)Blood, 2011
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory LeukemiaJournal of Clinical Oncology, 2011
- Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I ConsortiumJournal of Clinical Oncology, 2011
- Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trialThe Lancet Oncology, 2010
- Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLBlood, 2010
- Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2009
- Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupBlood, 2009
- Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2008
- Improved outcome after relapse in children with acute myeloid leukaemiaBritish Journal of Haematology, 2006